American Journal of Pharmacological Sciences
ISSN (Print): 2327-6711 ISSN (Online): 2327-672X Website: Editor-in-chief: Srinivas NAMMI
Open Access
Journal Browser
American Journal of Pharmacological Sciences. 2014, 2(5B), 4-7
DOI: 10.12691/ajps-2-5B-2
Open AccessResearch Article

Polio Cost Effectiveness in Nigeria; A Lesson to Be Learnt


1Bachelor of Pharmacy University of Karachi, Master of Philosophy in Pharmacognosy (course work completed), Master of Science International Health Policy and Management Brandeis University, Doctoral Student (Public Health Education) Southern Illinois University Carbondale

Pub. Date: December 04, 2014
(This article belongs to the Special Issue Optimizing Patient Care through Effective Pharmacy Practice Models)

Cite this paper:
S. M. ZEESHAN QADAR. Polio Cost Effectiveness in Nigeria; A Lesson to Be Learnt. American Journal of Pharmacological Sciences. 2014; 2(5B):4-7. doi: 10.12691/ajps-2-5B-2


This review paper highlights the importance of a cost effective intervention in global polio eradication fight for developing nations. The main aim of this paper is to propose an intervention which is highly cost effective for Nigeria where polio is still prevalent. This paper examines cost effectiveness analysis of a feign one-year vaccination intervention using the oral polio vaccine (OPV) in Kano State, Nigeria. To establish cost-effectiveness healthy days saved by this vaccination intervention were used instead of Disability Adjusted Life Years (DALYS). In this case cost effectiveness was established by dividing intervention cost ($1.7 million) to the number of healthy days saved ($2485) to get cost per day of healthy life ($472). This cost effective intervention gives about $472 cost per day of healthy life which was then compared with the GDP per income of Kano ($1288). It was evident from the results of the study that as the cost of the intervention is below the GDP per capita of Kano, Nigeria which means this method is highly cost efficient. The cost effectiveness of this intervention implies that the program of vaccination is economically viable and should therefore be encouraged, than just concentrating on treating polio. With the economic crunch times in the world, there is a strong urge for cost effective programs to address for deadly diseases and the evaluated intervention would be one of them.

developing nations polio Kano Nigeria OPV (Oral Polio Vaccine) small pox

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  C-GIDD (CanBank Global Income Distribution database), 2008
[2]  CIA: The World Factbook, 2008. Retrieved on 03/24/09 at
[3]  Global Polio Eradication Initiative Website, 2012. Retrieved on 03/11/12 from
[4]  Global Polio Eradication Initiative Website, 2009. Retrieved on 03/25/09 from
[5]  Kahn, M, & Ehreth, J. 2003. Costs and benefits of polio eradication: a long run global perspective. Vaccine 21: 702-705.
[6]  Kahn, M, 2010. Economic Costs and Disability-Adjusted Life Years in Polio Eradication: A Long-Run Global Perspective. Springer Science Business Media LLC, 78: 1354-1371.
[7]  Singh, J et al, 1992. Epidemiological evaluation of Oral polio vaccine efficacy in Delhi, India. Journal of Pediatrics 59: 321-323.
[8]  Tanzania Malaria Operational Plan, 2008. Retrieved from
[9]  WHO Polio case count, 2009. Retrieved on 03/24/09 at
[10]  WHO press release WHO/83, Nov 24, 1994.
[11]  WHO Statistical Information System (WHOSIS), 2008.
[12]  WHO, UNICEF, CDC, December 2007. Global Polio Eradication Initiative Monthly Situation Report.